Scientists at The Wistar Institute have engineered a DNA-delivered bispecific T cell engager using a 'knob-into-hole' ...
Many think the next standard cancer treatment will pair two innovations.
Wistar scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian cancer in ...
Wistar scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian cancer in ...
Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...
Insight On More Than 60 Bispecific Antibody Drug Conjugates In Clinical Trials Bispecific Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase The mechanism of ...
Restricting step-up dosing and acute triage to a defined T-cell engaging team improves safety and consistency, with patients transitioning back to primary oncologists after stabilization. Standardized ...
Xencor's XmAb819 demonstrated a 25% response rate and 70% disease control in heavily pre-treated ccRCC patients. Read why ...
Bispecific antibodies have emerged as a transformative class of therapies in multiple myeloma and beyond, but the need for ...
LAS VEGAS, Sept. 15, 2025 /PRNewswire/ -- DelveInsight's Bispecific Antibodies in Oncology Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive ...
Structure-free AI platform delivers picomolar leads while cutting wet-lab validation to 20-50 samples per round The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results